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Strengths and limitations of this study
 ► This is the first systematic review that synthe-
sises the literature concerning alpha- blocker 
discontinuation.
 ► The review was conducted in accordance with the 
Preferred Reporting Items for Systematic Reviews 
and Meta- Analyses guidelines.
 ► The number of studies that could be included was 
limited, and the risk of bias was high for most out-
comes preventing the drawing of firm conclusions.
AbStrACt
Objectives We aimed to synthesise the available data 
for the effect of stopping alpha- blocker therapy among 
men with lower urinary tract symptoms. The focus was on 
symptom, uroflowmetry and quality of life outcomes, but 
we also reviewed the adverse events (AEs) and the number 
of patients who restarted therapy.
Data sources We searched MEDLINE/PubMed, EMBASE/
Ovid and The Cochrane Central Register of Controlled Trials 
from inception to May 2018.
Eligibility criteria We selected studies regardless of 
study design in which men were treated with an alpha- 
blocker for at least 3 months and in which the effects of 
alpha- blocker discontinuation were subsequently studied. 
Only controlled trials were used for the primary objective.
Data extraction and synthesis Two reviewers 
independently extracted data and assessed the risk of 
bias for the controlled studies only using the Cochrane 
Collaboration’s tool for assessing risk of bias. Data were 
pooled using random- effects meta- analyses.
results We identified 10 studies (1081 participants) 
assessing the primary objective. Six studies (733 
participants) assessed differences in AEs between 
continuation and discontinuation, and six studies (501 
participants) reported the numbers of subjects that 
restarted treatment after discontinuation. No studies 
in primary care were identified. After discontinuing 
monotherapy, symptom scores increased and peak 
flow rates decreased at 3 and 6 months, but not at 12 
months; however, neither parameter changed when alpha- 
blockers were stopped during combination therapy. Small 
differences in post- void residual volumes and quality of 
life scores were considered clinically irrelevant. We also 
found that 0%–49% of patients restarted after stopping 
alpha- blocker therapy and that AEs did not increase with 
discontinuation.
Conclusions Discontinuing alpha- blocker monotherapy 
leads to a worsening compared with continuing therapy. 
Discontinuing the alpha- blocker after combination therapy 
had no significant effects on outcomes in either the 
short or long term. Discontinuation may be appropriate 
for the frail, elderly or those with concomitant illness 
or polypharmacy. However, studies in primary care are 
lacking.
PrOSPErO registration number CRD42016032648.
IntrODuCtIOn
Alpha- blockers are the first- choice treatment 
for men with moderate- to- severe lower urinary 
tract symptoms (LUTS) because of their proven, 
but small, superiority over placebo,1–3 but their 
use can be associated with dizziness, orthostatic 
hypotension and increased fall risk.3 4 This may 
be especially problematic in the elderly, who 
often have polypharmacy and multimorbidity. 
Given the natural course of LUTS, with 30% 
of patients showing improvement over time,5 
it may be appropriate to consider discontinua-
tion of alpha- blocker therapy, especially in the 
elderly. There are no clear data on the effect of 
this approach but the guideline on male LUTS 
for Dutch general practitioners (GPs) advises 
that alpha- blocker therapy be discontinued 
after 3–6 months, followed by symptom review.2 
By contrast, guidelines followed by urologists 
do not advocate routine discontinuation,1 6 
although the European Association of Urology 
(EAU) do mention that alpha- blocker discon-
tinuation may be considered after 6 months in 
the context of combination therapy.1
A number of researchers have studied the 
effects of discontinuing alpha- blockers, but 












pen: first published as 10.1136/bmjopen-2019-030405 on 7 November 2019. Downloaded from 
2 van der Worp H, et al. BMJ Open 2019;9:e030405. doi:10.1136/bmjopen-2019-030405
Open access 
We performed a systematic review and meta- analysis 
to obtain data about the effect of discontinuing alpha- 
blockers on male LUTS. Our primary objective was to 
compare the effects of discontinuing therapy with those 
of continuing therapy. Secondary objectives were (1) to 
determine the proportion of men who restarted alpha- 
blocker therapy and (2) to determine the possible adverse 
effects (AEs) of both discontinuation and continuation.
MEthODS
We completed this review according to the Preferred 
Reporting Items for Systematic Reviews and Meta- 
Analyses guidelines and registered the protocol in the 
PROSPERO database (CRD42016032648) (http://www. 
crd. york. ac. uk/ PROSPERO/ display_ record. php? ID= 
CRD42016032648).
Selection criteria
We selected studies in which men were treated with an 
alpha- blocker for at least 3 months and in which the effects 
of alpha- blocker discontinuation were subsequently 
studied. For the primary objective, only randomised 
controlled trials (RCTs, including quasi- randomised 
trials) and non- randomised trials (NRTs) that compared 
alpha- blocker discontinuation to continuation were 
selected. For the secondary objectives, we also included 
uncontrolled studies. At all stages, we excluded studies 
written in languages other than Dutch, English, French 
or German.
Outcome measures
The following outcomes were used for the primary objec-
tive: symptom scores, such as the International Prostate 
Symptom Score (IPSS); urinary flow rates; post- void 
residual urine volume (PVR); and quality of life (QoL). 
For the secondary objectives, we calculated the percentage 
of patients who restarted alpha- blocker therapy and the 
numbers of AEs in the continuation and discontinuation 
groups.
Search methods for identification of studies
We searched MEDLINE/PubMed, EMBASE/Ovid and 
The Cochrane Central Register of Controlled Trials 
using search terms covering LUTS, alpha- blockers and 
discontinuation (see online supplementary file 1 for 
detailed information). We ran the searches in January 
2016 and updated them in July 2017 and May 2018. The 
reference lists of relevant articles were also screened to 
identify additional eligible studies. All duplicate files were 
removed before the titles and abstracts of the remaining 
records were independently screened by three reviewers 
(IH, LK, MHB) and classified as ‘inclusion,’ ‘exclusion,’ 
or ‘uncertain.’ Next, the same reviewers independently 
applied the selection criteria to the full- text papers of all 
records classified into the inclusion or uncertain groups, 
and decided whether to include or exclude the research. 
Discrepancies in the selection procedure were resolved 
by consensus.
Data extraction process
Two authors (HvdW, IH) independently performed data 
extraction using standardised forms. We extracted the 
following data: (1) the participant characteristics; (2) 
the interventions used; (3) the primary and secondary 
outcomes, as well as the timing of the outcome assessment; 
and (4) the study design. If possible, we extracted data by 
allocated intervention to allow an intention- to- treat anal-
ysis. Discrepancies were resolved by re- examination and 
discussion of the full- text papers or by consultation with a 
third author (MHB).
risk of bias
Two reviewers (HvdW, YL- vL) independently assessed the 
risk of bias using the Cochrane Collaboration’s tool for 
assessing risk of bias.7 This tool includes six domains, as 
follows: selection bias, performance bias, detection bias, 
attrition bias, reporting bias and other bias. Only RCTs 
and NRTs were assessed because these were used for the 
primary objective. Discrepancies in the risk of bias assess-
ment were resolved by consensus or arbitration with a 
third party (MHB). Risk of bias was described for the five 
domains (selection, performance, attrition, reporting and 
other) and summarised across studies and outcomes.7 To 
ascertain graphically the existence of publication bias, 
the construction of funnel plots was planned in case at 
least 10 studies were included.
Data analysis
Data were analysed using Review Manager, V.5.3.8 We 
calculated the risk difference and 95% CIs for dichoto-
mous variables (inverse- variance method) and the mean 
differences (MD) with 95% CIs for continuous variables 
(Mantel- Haenszel method). For AEs, we also calculated 
the rate of AEs per 1000 patient- days based on the sample 
sizes and follow- up times.
Clinical heterogeneity was assessed by checking the 
characteristics of participants and interventions. Statis-
tical heterogeneity was assessed by visual inspection of 
the forest plots and of the results of statistical testing for 
heterogeneity (I2 statistic). We pooled data if we iden-
tified two or more studies with an I2 of <40%,9 using a 
random effects model. Data from both RCTs and NRTs 
were pooled. Synthesising and pooling were done sepa-
rately for monotherapy and combination therapy. If 
the data for pooling were only presented in figures (eg, 
SD), it was extracted from those figures. If data were not 
present at all in the article, we contacted the authors if 
the article had been published in the past 10 years. If data 
could not be obtained in this way, we imputed data from a 
previous meta- analysis on the efficacy of alpha- blockers,3 
as described in the Cochrane Handbook.9 10
The following cut- off values were used to define the 
minimal clinical important difference (MCID): 2.7 
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the IPSS- QoL scores.3 The MCID is the smallest change 
in a treatment outcome that an individual patient would 
identify as important and which would indicate a change 
in the patient’s management.
Patient and public involvement
This study was performed without patient involvement. 
The patients were not invited to comment on the study 
design and were not consulted to interpret the results. 
The patients were not invited to contribute to the writing 
or editing of this document for readability or accuracy.
rESultS
The searches yielded 1039 publications (online supple-
mentary file 2), of which 16 with a total of 1823 partici-
pants were included (table 1). All included studies were 
performed in secondary or tertiary care. Nine studies 
(772 participants) reported discontinuing alpha- blocker 
monotherapy: two double- blind RCTs,12 13 two open- label 
RCTs,14 15 one NRT16 and four uncontrolled studies.17–20 
Six studies (980 participants) reported discontinuing 
alpha- blockers used in combination therapy: one double- 
blind RCT,21 four open- label RCTs22–25 and one uncon-
trolled study.26 Finally, one uncontrolled study (n=71) 
reported discontinuing both alpha- blocker monotherapy 
and combination therapy.27
Two of the included studies randomised patients into 
three groups: a discontinuation group, a continuation 
group and a third group that continued with alternate- day 
use of alpha- blockers.14 15 We only used the data from the 
discontinuation and continuation groups.
In another three studies, the data required for pooling 
were missing.12 13 21 Because these studies had been 
published over 15 years previously, no efforts were made 
to contact the authors. For one of the studies, means and 
SD could be obtained from the figures.13 For the other 
two studies,12 21 the SD were missing and were imputed 
from the results of a previous meta- analysis (see online 
supplementary file 3).3 No studies were excluded form 
pooling based on statistical heterogeneity.
risk of bias
Most of the included studies had risks of bias (online 
supplementary file 4). The most common were lack of 
blinding and randomisation, with only 3 out of 10 studies 
having a ‘low risk’ for these items. There was no evidence 
of reporting bias in any of the included studies. The 
summary of bias by study indicated that only one study 
had low risk of bias,12 while two studies had unclear risks 
of bias,13 21 and the remaining studies had high risks of 
bias.14–16 22–25 As a result, risk of bias was high for all but 
one outcome.
We did not construct funnel plots to ascertain the exis-
tence of publication bias graphically, as the number of 
included studies in each meta- analysis was less than 10.
Effects of alpha-blocker discontinuation
Five studies of monotherapy (n=341)12 13 15 16 and five 
studies of combination therapy (n=740)21–25 were used 
for the primary research objective. Only three provided 
data on the number of patients who did not comply 
with the intervention and who restarted alpha- blocker 
use after discontinuation. Two of these provided a per 
protocol analysis excluding those patients24 25 and the 
third provided an intention- to- treat analysis for catego-
rised variables, with a per protocol analysis for the raw 
outcomes,23 effectively precluding an intention- to- treat 
analysis. Because all included studies reported outcomes 
at 3, 6 or 12 months, we compared outcomes at these time 
points.
 Symptom scores
All but one study13 assessed symptoms with the IPSS ques-
tionnaire, or its predecessor the American Urological 
Association (AUA) symptom score (n=1054).
By 3 months after discontinuing alpha- blocker mono-
therapy, symptoms increased in the discontinuation 
group compared with the continuation group (MD=4.17; 
95% CI 2.91 to 5.43),14 15 whereas there was no difference 
between the continuation and discontinuation groups in 
the studies of combination therapy (MD=0.97; 95% CI 
−0.32 to 2.27, figure 1A).21 25
After 6 months, two RCTs and one NRT on mono-
therapy found a significant worsening of symptoms 
(differences varying from 2.0 to 5.8 points) in subjects 
that discontinued alpha- blockers.12 14 15 No difference was 
found for studies on combination therapy after 6 months 
(MD=0.56; 95% CI −1.57;2.69, figure 1B).24 25
After 12 months, the one study that looked at discontin-
uing monotherapy found a non- significant difference of 
1.2 points between groups.16 No differences were found 
in two open- label RCTs that looked at alpha- blocker 
discontinuation after combination therapy.22 23 Another 
NRT presented data for both groups, but did not make 
a direct statistical comparison between groups.25 Data 
could not be pooled (I2=61%).
 Peak urine flow rate
Nine studies (804 patients) assessed peak urine flow rate 
(Q- max): five studies for monotherapy,12–16 and four 
studies for combination therapy.22–25
After 3 months, Q- max was reduced by 2.59 mL/s (95% 
CI 1.40 to 3.77, figure 2A) in those who discontinued 
alpha- blocker monotherapy compared with those who 
continued therapy.13–15 A single study on discontinuing 
combination therapy found that there was an increase 
of 1.4 mL/s in those who discontinued compared with 
those who continued therapy, but the researchers did not 
perform a statistical comparison.25
After 6 months, a reduction was again found in the 
Q- max after discontinuing monotherapy (MD=1.79; 95% 
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Figure 1 Forest plots of the IPSS when discontinuing or continuing alpha- blockers. (A) Forest plot of the IPSS after 3 months 
for alpha- blocker discontinuation or continuation. (B) Forest plot of the IPSS after 6 months for alpha- blocker discontinuation or 
continuation. IPSS, International Prostate Symptom Score.
discontinuing in the context of combination therapy 
(MD −0.23; 95% CI −1.51 to 1.05, figure 2B).24 25
After 12 months, no differences were found in an NRT 
reporting on the effects of discontinuing monotherapy.16 
Three studies assessed Q- max 12 months after combina-
tion therapy. Among these, two open- label RCTs found 
no difference between groups22 23: one study found 
a difference of 0.1 mL/s in favour of the continuation 
group and the other found that 7% fewer patients in the 
discontinuation group had a reduction in Q- max of >2 
mL/s compared with the continuation group. Again, 
the NRT on combination therapy showed an increase of 
2.5 mL/s after alpha- blocker discontinuation, which was 
not seen in the group that continued alpha- blockers, but 
differences were not tested.25 Data could not be pooled 
(I2=68%).
 Average urine flow rate
Data from two RCTs on monotherapy (84 patients) could 
not be pooled (I2=70%).13 14
After 3 months, one RCT reported a reduction of 2.2 
mL/s in subjects who discontinued therapy compared 
with those who continued therapy,13 whereas no statistical 
testing of the difference of 0.6 mL/s between groups was 
performed in the other RCT.14
After 6 months, this second study found a difference 
of 0.9 mL/s between groups in favour of continuing 
monotherapy.14
 Post-void residual volume
PVR was measured in five studies (n=468), with three 
measuring it after discontinuing monotherapy13 14 16 and 
two measuring it after discontinuing the alpha- blocker in 
combination therapy.22 23
After 3 months, discontinuing monotherapy resulted 
in a PVR increase of 9.98 mL (95% CI 0.84 to 19.12, 
figure 3).13 14
After 6 months, an open- label trial on discontinuing 
monotherapy (57 participants) also found a statistically 
significant difference (14.1 mL) in favour of continuing 
therapy.14
At 12 months after discontinuing monotherapy, 
an NRT did not find a significant difference between 
groups.16 Two open- label RCTs on discontinuing combi-
nation therapy did report non- significant differences: 
one showed a 2 mL difference between groups,22 and the 
other showed that 8% more patients in the discontinua-
tion group reported a PVR increase of >50%.23
 Quality of life
All five studies (one of monotherapy and four of combi-
nation therapy; 677 patients) that assessed QoL used the 
IPSS QoL subscore.
After 3 months, one study of combination therapy 
found no difference between groups (0 point).21 In 
another NRT of combination therapy, a difference of 0.4 
point was reported in favour of the group that discon-











pen: first published as 10.1136/bmjopen-2019-030405 on 7 November 2019. Downloaded from 
7van der Worp H, et al. BMJ Open 2019;9:e030405. doi:10.1136/bmjopen-2019-030405
Open access
Figure 2 Forest plots of the Q- max when discontinuing or continuing alpha- blockers. (A) Forest plot of the Q- max 3 months 
after alpha- blocker discontinuation or continuation. (B) Forest plot of the Q- max 6 months after alpha- blocker discontinuation or 
continuation. Q- max, peak urine flow rate.
Figure 3 Forest plot of the PVR 3 months after discontinuing or continuing alpha- blockers. PVR, post- void residual urine 
volume.
After 6 months, one study on monotherapy found a 
statistically significant difference of 0.2 point in favour 
of those who continued alpha- blocker therapy.12 This 
was the only outcome with a low risk of bias. A difference 
was found for the pooled studies of combination therapy 
(MD=0.42; 95% CI 0.11 to 0.73, figure 4).24 25
After 12 months, no differences in QoL scores (only 
0.1 point in favour of discontinuation) were found in an 
RCT of 117 participants receiving combination therapy.22 
Another NRT of patients receiving combination therapy 
found a difference of 0.4 in favour of continuation, but 
did not compare groups statistically.25 Data could not be 
pooled (I2=60%).
restart of prior treatment and AEs
 Patients restarting treatment
Six studies (501 patients) reported data on restarting 
alpha- blockers after discontinuation.16 17 20 23–25 In three 
of these (187 patients), 7%–49% of subjects restarted 
alpha- blockers after 6 months.17 20 24 One of these,20 
together with another three studies (374 patients),16 23 25 
described that 0%–33% of subjects had restarted alpha- 
blockers at 12 months. The highest (49%) and lowest 
percentages (0%) restarting therapy were found in 
studies of monotherapy.16 17 However, four of the 
included studies explicitly advised subjects to restart 
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Figure 4 Forest plot of the QoL score 6 months after discontinuing or continuing alpha- blockers. QoL, quality of life.
Figure 5 Forest plot of AEs after discontinuing or continuing alpha- blockers. AEs, adverse events.
symptoms worsened.23 25 These studies reported the 
highest restart rates.
Three other studies provided indirect information 
about restarting alpha- blocker use.18 26 27 Two of these 
reported on successful discontinuation, defined as no 
increase in symptoms and no request for continuation of 
treatment. After 6 months, one indicated success among 
69% of those receiving monotherapy.18 Another study 
reported success rates of 13%–87% 1 month after discon-
tinuing combination therapy, with percentages increasing 
as the duration of alpha- blocker use increased (ranging 
from 3 to 12 months).26 Discontinuation was successful 
in 13%–20% of subjects who used alpha- blockers for 3 
months and in 84%–87% of subjects who used them for 
12 months. A third study stated that most patients whose 
symptoms worsened after discontinuation wished to 
restart their medication rather than undergo surgery.27
 Adverse events
Nine studies provided no data on AEs during discon-
tinuation, or if they did, provided data without a clear 
indication of the treatment group.24 Another study 
only reported AEs during follow- up for those who 
discontinued alpha- blockers.19 The six remaining studies 
reported 49 AEs in 363 patients who discontinued alpha- 
blockers and 58 AEs in 370 patients who continued to 
use alpha- blockers.12–15 21 22 The AE rates in patients who 
discontinued or continued alpha- blockers were 0.13 and 
0.15 per 1000 patient- days, respectively. The pooled data 
showed no risk difference for AEs when discontinuing or 
continuing either monotherapy (risk difference=−0.01; 
95% CI −0.08 to 0.07) or combination therapy (risk differ-
ence=−0.03; 95% CI −0.07 to 0.01, figure 5).
Respiratory tract infection and urinary retention were 
the two most common AEs after discontinuing alpha- 
blockers (11 studies in total), being reported in 1%–4% 
of patients12 21 and in 1%–3% of patients,12 22 respectively. 
The incidence of these AEs did not differ between groups.
DISCuSSIOn
The results of this systematic review indicate that discon-
tinuing alpha- blocker monotherapy leads to a worsening 
of clinical symptoms and a decrease of urinary flow rates 
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therapy. However, after 1 year, no differences were found 
in these or other outcomes. Discontinuing the alpha- 
blocker after combination therapy had no significant 
effects on outcomes in either the short or the long term.
The worsening of symptoms over the short term after 
stopping monotherapy was probably relevant to clinical 
practice. The reported differences in the IPSS between 
groups exceeded the MCID of 2.7 points.11 The differ-
ence in Q- max was also clinically relevant, exceeding the 
MCID of 2 mL/s after 3 months (between- group differ-
ence, 2.59 mL/s),3 but not after 6 months (1.79 mL/s). 
One might argue about the relevance of this outcome for 
patient, as men will not be able to notice a difference in 
flow rate at these values. The difference of 0.42 point in 
the QoL scores at 6 months after discontinuing combi-
nation therapy remained below the MCID of 0.5 point.3 
Although no MCID was available for PVR, we do not 
think that the reported mean difference of 10 mL after 3 
months was clinically relevant.
The worsening of symptoms noted by 3–6 months after 
discontinuing monotherapy was larger than the reported 
improvement of symptoms after initiating therapy, which 
was reported to be 2.55 points (95% CI, 1.92 to 3.17) 
based on 12 RCTs with a total of 9335 participants.3 The 
magnitude of change in the present review may have been 
influenced by the lack of blinding of both patients and 
assessors in many of the studies, which will have favoured 
the continuation groups. Men in these studies who had no 
clear symptom improvements are likely to have dropped 
out before the discontinuation phase, so the participants 
subsequently included in the discontinuation trials will 
generally have had larger treatment effects and larger 
changes after discontinuation. The outcomes after 12 
months relied on data from a single study on discontin-
uing doxazosin (not a controlled- release version),16 which 
has a lower efficacy than other alpha- blockers. This might 
explain the lack of any meaningful long- term impact.
Among patients receiving combination therapy, 
outcomes were not significantly different between those 
discontinuing and continuing alpha- blockers. Although 
5- alpha- reductase inhibitors have no significant impact on 
LUTS severity after treatment initiation,28 29 their contin-
uation seems to be protective against symptom worsening 
after discontinuing alpha- blockers.
The results for restarting a discontinued alpha- blocker 
were heterogeneous, ranging widely from 0% to 49%. 
These conflicting findings can be explained by the differ-
ences in instructions given to patients in these studies. 
Indeed, participants in some studies received explicit 
instructions about when to restart therapy, whereas in 
other studies, no instructions were given. Also, subjects 
in cohort studies who volunteered to discontinue therapy 
may have had greater freedom to restart therapy than 
those participating in an RCT.
It was also shown that discontinuing alpha- blockers did 
not result in more AEs, including acute urinary reten-
tion.30 Equally, continuation was not associated with more 
AEs, with neither dizziness nor orthostatic hypotension 
being more common.4 This may be explained by subject 
dropout due to AEs before entering the discontinua-
tion phase. The number of patients reporting AEs in the 
included studies was, however, too small to draw mean-
ingful conclusions regarding AEs.
Interpretation of our findings is hampered by some 
limitations. For example, the limited numbers of studies 
and large amount of statistical heterogeneity limited data 
pooling. Heterogeneity, especially on IPSS outcomes 
after 6 months could be explained by differences in 
alpha- blockers studied and baseline symptom severity 
differences ranging from 12 to 19 in the included studies. 
The limited number of RCTs also precluded sensitivity 
analyses, and subgroup analyses, that were planned in 
the original review protocol. Another limitation related 
to the limited number of studies is the reduction in statis-
tical power. It has been shown that at least five studies 
have to be pooled to achieve a greater power than the 
original studies independently.31 So, our results could 
also be subject to type I error. In addition, some studies 
gave unclear data about treatment compliance or only 
presented per protocol analyses, which may have led 
to bias (eg, dropout due to severe complaints) and loss 
of generalisability. Another issue is that all studies were 
performed in secondary or tertiary care settings. This is 
important if we consider that in some countries, most 
men with LUTS are treated in primary care. The high 
risk of bias, which was noted for all but one outcome, also 
hampers the interpretation of our findings. Finally, two 
of the trials of combination therapy compared discontin-
uing alpha- blockers and 5- alpha- reductase inhibitors, but 
the others compared discontinuing and continuing only 
the alpha- blocker.23 25
No firm conclusions can be drawn from this review 
because of the low quality of the available evidence. 
Overall, the data suggest that there is a short- term clin-
ical worsening of LUTS after discontinuing alpha- blocker 
monotherapy, as assessed by symptom scores and urinary 
flow rates, but that this does not increase the risk of a 
complicated symptom course.
Patients frequently discontinue alpha- blocker treat-
ment in clinical practice. We have recently shown that 
men who continue to use alpha- blockers are typically 
unconcerned about stopping that therapy if advised to 
do so by a doctor.32 The present review also provides 
evidence that the magnitude of symptom deterioration 
is limited, indicating that physicians can change their 
prescribing policy without risking harm. Indeed, the 
alternative approach may promote unnecessary polyphar-
macy, which is especially relevant in vulnerable groups. 
Active follow- up should then be used to monitor the need 
to restart alpha- blockers if symptoms worsen.
Our findings support the existing EAU guidance 
to consider discontinuing alpha- blockers in patients 
receiving combination therapy for 6 months.1 Unfor-
tunately, because the studies in this review were only 
performed in secondary care, we cannot give firm support 
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to review therapy after 3–6 months in primary care.2 
Symptom levels before treatment are generally lower in 
primary care, where conditions are typically less severe 
than in secondary care. Although the data from this 
review may be applicable to primary care, further efficacy 
studies and discontinuation trials are needed to assess the 
outcomes specific to this setting.
twitter Marco H Blanker @Marco_Blanker
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